As morbidity and mortality related to potentially preventable liver diseases are on the rise
globally, early detection of liver fibrosis offers a window of opportunity to prevent disease …

Purpose Non-alcoholic fatty liver disease (NAFLD) has become a leading cause of liver
disease, affecting 30% of the global population. NAFLD prevalence is particularly high in …

Liver fibrosis is a disease with significant morbidity and mortality. It is a chronic pathological
process characterized by an imbalance of extracellular matrix production and degradation in …

Liver fibrosis is a key pathophysiology process in chronic liver disease. It is still unclear
whether the impact of liver fibrosis is not fully realized in type 2 diabetes mellitus (T2D) …

Liver fibrosis is a liver disease in which there is an excessive buildup of extracellular matrix
proteins, including collagen. By regulating cytokine production and the inflammatory …

Metformin is a first-line oral antidiabetic agent that results in clear benefits in relation to
glucose metabolism and diabetes-related complications. The specific regulatory details and …

Altered metabolic function has many detrimental effects on the body that can manifest as
cardiovascular and liver diseases. Traditional approaches to understanding and treating …

Fatty liver disease (FLD) is a well-known metabolic disorder associated with hepatic
steatosis and tissue lipid accumulation. Metabolic dysfunction-associated fatty liver disease …

Aims Metabolic dysfunction-associated fatty liver disease (MAFLD) is common in people
with type 2 diabetes (T2D) and can progress to advanced fibrosis and cirrhosis. In this …

Metformin is a highly effective medication for managing type 2 diabetes mellitus. Recent
studies have shown that it has significant therapeutic benefits in various organ systems …